January 14, 2013

CAS databases provide millions of journal article references from more than 10,000 major scientific journals worldwide, patent and patent family references from 63 patent authorities around the world, and other reputable web sources.  

The following patent record is from the CAplusSM database.

CAPLUS COPYRIGHT 2013 ACS

Patent Number: WO 2012145471
Title: Preparation of morpholinosulfonyl indole compounds as modulators of insulin-like growth factor I receptors and insulin receptors for treating cancer
Inventor(s): Balachandran, Sarala; Dinsmore, Christopher J.; Roychowdhury, Abhijit; Sharma, Rajiv; Vishwakarma, Ram Asrey
Patent Assignee(s): Merck Sharp & Dohme Corp., USA; Piramal Healthcare Ltd.
Source: PCT Int. Appl., 140pp. CODEN: PIXXD2
Language: English

Abstract:

The present invention relates to compds. of general formula I (wherein R1 is H, halo, NO2, etc.; R2 is H or C1-C6 alkyl; R3 is (un)substituted; heterocyclyl, C1-C6 alkylene, etc.; R9 is (un)substituted C6-C10aryl, (un)substituted 5-10 membered heterocyclyl, etc.) that are capable of inhibiting, modulating and/or regulating insulin-like-growth factor I receptors and insulin receptors and can be used for cancer treatment.  The present invention is also related to the pharmaceutically acceptable salts, hydrates and stereoisomers of these compds.  Synthetic procedures for preparing I are exemplified. Example compound II was prepared in a 7-step synthesis that culminated in reaction of intermediate III with Et 4-oxopiperidine-1-carboxylate. Example compds. were tested in (1) in vitro IGF-IR and IR kinase assays, (2) antiproliferation assays using breast cancer and colon cancer cells, and (3) CYP inhibition assays.

View the full-text patent here.

Note: Abstracts and Titles for patent records in CAplus are routinely enhanced to better describe the claimed invention. In this example, CAS enhanced the abstract using additional information found in the patent. The original title of the PCT publication is Insulin-like growth factor-1 receptor inhibitors.

Recent News


    August 3, 2015 | New STN Breaks Ground with
    Markush Structure Search and Enhanced Content
    for Intellectual Property Exploration and Research
   
    June 29, 2015 | CAS Assigns the 100 Millionth CAS
    Registry Number to a Substance Designed to
    Treat Acute Myeloid Leukemia
   
    March 17, 2015 | New Content Provides Regulatory
    Professionals with Additional Value

                                                                       More News >> 
 
 

Media Contact

 Name: Rhonda Ross
 Phone: 614-447-3624
 Email: cas-pr@cas.org